Mats Blom

Mr. Mats Blom is a Chairman at Egetis Therapeutics AB, an Independent Director at Hansa Biopharma AB and an Independent Non-Executive Director at Altamira Therapeutics Ltd. He is on the Board of Directors at Pephexia Therapeutics ApS, Hansa Biopharma AB, Altamira Therapeutics Ltd. and Auris Medical AG.
Mr. Blom was previously employed as a Chief Financial Officer by NorthSea Therapeutics BV, a Chief Financial Officer by Modus Therapeutics AB, an Independent Non-Executive Director by Auris Medical Holding AG /Old/, a Chief Financial Officer & Executive Vice President by Zealand Pharma A/S, a Chief Financial Officer by Swedish Orphan International Holding AB, a Chief Financial Officer by Anoto Group AB, a CFO & Vice President-Business Development by Active Biotech AB, and a Chairman by Immedica Pharma AB. He received his undergraduate degree from the University of Lund and an MBA from the Instituto de Estudios Superiores de la Empresa.